缺血性进展性脑卒中的临床治疗与观察  

Curative Effect Observation and Analysis of Shuxuetong Injection Combined with Edaravone in the Treatment of Stroke in Progression

作　　者：王晓霞[1] 杨巧莲[1] 谢竟芳[2] 

机构地区：[1]包头医学院第一附属医院神经内科,内蒙古包头014010 [2]包头医学院流行病学教研室,内蒙古包头014010

出　　处：《内蒙古医学杂志》2010年第5期533-535,共3页Inner Mongolia Medical Journal

摘　　要：目的:观察依达拉奉联合疏血通治疗缺血性进展性卒中(Stroke in progression,SIP)的临床效果,分析进展性卒中的病理生理及依达拉奉治疗的机理。方法:将86名急性进展性卒中患者随机分为治疗组和对照组。治疗组在基础治疗同时给予疏血通和依达拉奉治疗,对照组给予疏血通及常规治疗。比较两组治疗前后神经功能缺损评分和疗效的变化。结果:每组用药后临床神经功能缺损程度评分明显降低,治疗组疗效优于对照组。不良反应:用药后5例肾功能异常,3例转氨酶升高,1周后均恢复正常。结论:依达拉奉治疗缺血性进展性卒中是有效的安全的,未有严重的不良反应发生。Objective：To observe the efficacy and safety of Shuxuetong injection combined with Edaravone in the treatment of Stroke in progression.Methods：Eighty-six patients of Stroke in progression were randomly divided into two groups,the treatment group was given with Shuxuetong injection and Edaravone.and the control group was treated by Shuxuetong injection.Two groups were treated with routine therapy.Changes of neurologie defect and curative effect in two groups were assessed at different points before and after treatment.Results：The scores of neurologic defect of two groups decreased after treatment,but which in the treatment group was dramatically decreased,there was significant difference between the two groups（P0.05）.After treatment with Edaravone,there were 5 case of abnormal renal function and 3 case of increased transaminase.Conclusion：Shuxuetong injection combined with Edaravone is an effective and safe treatment for acute Stroke in progression.

关 键 词：缺血性进展性卒中 依达拉奉 疏血通 

分 类 号：R743.3[医药卫生—神经病学与精神病学]